The text starts here.

News Release

Information in the news releases is current on the date of the announcement, but is subject to change without prior notice.

2016 Release

December 22, 2016 EISAI AND KEIO UNIVERSITY TO ESTABLISH A NEW INDUSTRY-ACADEMIA COLLABORATION SITE
ACCELERATING THE DISCOVERY OF NOVEL DRUG TARGETS THAT MAY LEAD TO DEVELOPMENT OF NEW THERAPEUTICS FOR DEMENTIA
December 20, 2016 ANTI-OBESITY AGENT BELVIQ® APPROVED IN BRAZIL
December 19, 2016 ANTICANCER AGENT TREAKISYM® APPROVED IN JAPAN FOR ADDITIONAL INDICATION AS FIRST-LINE TREATMENT FOR LOW-GRADE B-CELL NON-HODGKIN'S LYMPHOMA AND MANTLE CELL LYMPHOMA
December 12, 2016 EISAI PRESENTS LATEST DATA ON BACE INHIBITOR ELENBECESTAT(E2609) AT 9TH CLINICAL TRIALS ON ALZHEIMER'S DISEASE
December 12, 2016 INTERIM ANALYSIS OF PHASE Ib/II STUDY OF ERIBULIN AND PEMBROLIZUMAB COMBINATION REGIMEN IN METASTATIC TRIPLE NEGATIVE BREAST CANCER PRESENTED AT SAN ANTONIO BREAST CANCER SYMPOSIUM
November 30, 2016 EISAI TO PRESENT LATEST DATA ON PERAMPANEL AND RUFINAMIDE AT 70TH AMERICAN EPILEPSY SOCIETY ANNUAL MEETING
November 30, 2016 EISAI TO PRESENT LATEST DATA ON ERIBULIN AT 39TH ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM
November 18, 2016 U.S. FDA GRANTS FAST TRACK DESIGNATION FOR THE DEVELOPMENT OF EISAI’S BACE INHIBITOR E2609 FOR EARLY ALZHEIMER’S DISEASE
November 14, 2016 STATEMENT REGARDING THE RESULTS OF THE ACCESS TO MEDICINE INDEX 2016
November 4, 2016 U.K. NICE RECOMMENDS ANTICANCER AGENT HALAVEN® AS TREATMENT FOR ADVANCED BREAST CANCER
October 31, 2016 ENROLLMENT COMMENCES IN PHASE III CLINICAL STUDY OF EISAI'S BACE INHIBITOR E2609 IN EARLY ALZHEIMER'S DISEASE
October 31, 2016 Notification Regarding Revision of Consolidated Financial Forecasts (IFRS) for the Fiscal Year Ending March 31, 2017
October 28, 2016 EISAI TO INITIATE PHASE II CLINICAL STUDY OF DUAL OREXIN RECEPTOR ANTAGONIST LEMBOREXANT IN PATIENTS WITH IRREGULAR SLEEP-WAKE RHYTHM DISORDER AND DEMENTIA
October 28, 2016 EISAI TO INITIATE TWO PHASE III CLINICAL STUDIES FOR ANTIEPILEPTIC DRUG PERAMPANEL (FYCOMPA®) IN PEDIATRIC PATIENTS WITH PARTIAL-ONSET OR PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AND IN PATIENTS WITH SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME
October 28, 2016 Application Submitted for Proton Pump Inhibitor Pariet® in Japan Seeking Approval for Additional Dosage and Administration for Maintenance Therapy of Proton Pump Inhibitor Resistant Reflux Esophagitis
October 13, 2016 EISAI TO OFFICIALLY LAUNCH “CHOCOLA BB® RICH CERAMIDE” IN STORES NATIONWIDE
JAPAN'S FIRST FOOD WITH FUNCTION CLAIMS DRINK CONTAINING CERAMIDE
-“DRINK” TO COUNTER DRY SKIN -
October 12, 2016 PRELIMINARY PHASE IB CLINICAL STUDY RESULTS FOR LENVATINIB IN COMBINATION WITH PEMBROLIZUMAB IN SELECTED SOLID TUMORS PRESENTED AT ESMO 2016
October 4, 2016 EXCLUSIVE LICENSING AGREEMENT FOR IN-HOUSE DEVELOPED MONOCLONAL ANTIBODY FARLETUZUMAB IN LATIN AMERICA CONCLUDED WITH EUROFARMA LABORATÓRIOS S.A.
October 4, 2016 LAUNCH OF URITOS® TABLETS FOR OVERACTIVE BLADDER IN THAILAND
October 4, 2016 BELVIQ XR® - A NEW ONCE-DAILY FORMULATION OF BELVIQ® FOR CHRONIC WEIGHT MANAGEMENT NOW AVAILABLE IN THE UNITED STATES
September 30, 2016 EISAI TO INITIATE PHASE III CLINICAL STUDY OF ANTICANCER AGENT LENVATINIB AS POTENTIAL FIRST-LINE THERAPY FOR ADVANCED RENAL CELL CARCINOMA
SIMULTANEOUS DEVELOPMENT OF TWO COMBINATION THERAPIES LENVATINIB/EVEROLIMUS AND LENVATINIB/PEMBROLIZUMAB
September 29, 2016 EISAI TO PRESENT LATEST DATA ON LENVATINIB AND ERIBULIN AT ESMO CONGRESS 2016
September 28, 2016 AbbVie and Eisai Obtain Additional Approval for New Indication of Fully Human Anti-TNF-α Monoclonal Antibody HUMIRA® in the Treatment of non-infectious Uveitis
-The First Biologic Treatment Available for Non-Infectious Intermediate, Posterior and Panuveitis Regardless of Underlying Disease-
September 28, 2016 EISAI COMMENCES PROVISION OF “EMILY” SMARTPHONE APP TO SUPPORT LIVING WITH EPILEPSY IN JAPAN
FEATURES LOCALIZED SOS NOTIFICATION FOR EMERGENCIES AND EASY COMMUNICATION VIA STAMPS
September 27, 2016 EISAI SUBMITS SUPPLEMENTAL APPLICATION FOR PARTIAL LABEL CHANGE FOR ANTIEPILEPTIC DRUG FYCOMPA® AS MONOTHERAPY FOR TREATMENT OF PARTIAL-ONSET SEIZURES BASED ON NEW U.S. FDA POLICY
September 15, 2016 EISAI RECEIVES LICENSE FOR NEW INDICATION FOR ANTICANCER AGENT KISPLYX® ▼ (LENVATINIB MESYLATE) FOR TREATMENT OF ADVANCED RENAL CELL CARCINOMA
September 14, 2016 EISAI SELECTED FOR FOURTH CONSECUTIVE YEAR OF MEMBERSHIP IN DOW JONES SUSTAINABILITY ASIA PACIFIC INDEX 2016
August 26, 2016 ANTICANCER AGENT “TREAKISYM® FOR INJECTION 100 MG” APPROVED IN JAPAN FOR ADDITIONAL INDICATION OF CHRONIC LYMPHOCYTIC LEUKEMIA
August 23, 2016 EISAI TO LAUNCH CHOCOLA BB® MOUTH ULCER REPAIR SHOT
FIRST MOUTH ULCER SPRAY FOR THE CHOCOLA BB BRAND
August 9, 2016 U.S. FDA CONFIRMS SUFFICIENT DATA TO ADVANCE INVESTIGATIONAL BACE INHIBITOR E2609 FOR TREATMENT OF EARLY ALZHEIMER'S DISEASE TO PHASE III
PLANNING UNDERWAY TOWARDS PHASE III STUDY INITIATION IN FY2016
August 5, 2016 CHINA FOOD AND DRUG ADMINISTRATION ACCEPTS NDA FOR ANTICANCER AGENT HALAVEN®
August 3, 2016 CONTINUATION OF “POLICY FOR PROTECTION OF THE COMPANY'S CORPORATE VALUE AND COMMON INTERESTS OF SHAREHOLDERS (SHAREHOLDER RIGHTS PLAN)”
August 1, 2016 EISAI AND MAMORIO TO JOINTLY DEVELOP “ME-MAMORIO” TRACKING TOOL TO SUPPORT PEOPLE WITH DEMENTIA GOING OUT
August 1, 2016 EISAI PRESENTS RESULTS OF ADDITIONAL ANALYSIS OF PHASE III STUDY OF ANTICANCER AGENT HALAVEN® AT 14TH JSMO ANNUAL MEETING PLENARY SESSION
July 27, 2016 Notification Regarding Revision of Consolidated Financial Forecasts (IFRS)
July 22, 2016 EISAI RECEIVES POSITIVE CHMP OPINION ON NEW INDICATION FOR ANTICANCER AGENT LENVATINIB IN COMBINATION WITH EVEROLIMUS FOR TREATMENT OF ADVANCED RENAL CELL CARCINOMA
July 19, 2016 U.S. FDA APPROVES BELVIQ XR®, A ONCE-DAILY FORMULATION OF LORCASERIN FOR CHRONIC WEIGHT MANAGEMENT
July 14, 2016 ANTIOBESITY AGENT VENESPRI® (LORCASERIN) APPROVED IN MEXICO
FIRST COUNTRY IN LATIN AMERICA TO APPROVE LORCASERIN
July 13, 2016 Correction to “Notification Regarding the Continuation and Partial Revision of the Performance-Related Stock Compensation System”
July 11, 2016 NTT IT, NTT East and Eisai Rollout Interprofessional Collaboration Business for Medical Treatment and Care
July 4, 2016 EISAI LAUNCHES IN-HOUSE DEVELOPED NOVEL ANTICANCER AGENT LENVIMA® IN MEXICO
June 30, 2016 EISAI LISTED FOR 15TH CONSECUTIVE YEAR IN FTSE4GOOD INDEX SERIES, AN INDEX FOR SOCIALLY RESPONSIBLE INVESTMENT
June 27, 2016 Position and Policy Regarding Reduction in the Trading Unit of the Company's Shares
June 20, 2016 AbbVie, Eisai, and EA Pharma Obtain Additional Approval for New Dosing Regimen of Fully Human Anti-TNF-α Monoclonal Antibody Humira® in Patients with Crohn's Disease
June 16, 2016 Notice Regarding the Recording of One-time Income in Association with Acquisition of EA Pharma Shares
June 16, 2016 EISAI LAUNCHES NEW ORAL SUSPENSION FORMULATION FOR ANTIEPILEPTIC DRUG FYCOMPA® (PERAMPANEL) IN THE UNITED STATES
As Adjunctive Therapy for the Treatment of Partial-Onset Seizures and Primary Generalized Tonic-Clonic Seizures in Patients with Epilepsy
June 13, 2016 EISAI PRESENTS LATEST PHASE I/II DATA ON IN-HOUSE DEVELOPED ANTI-FRACTALKINE ANTIBODY E6011
RESULTS SUGGEST SAFETY, TOLERABILITY AS WELL AS CLINICAL ACTIVITY IN RHEUMATOID ARTHRITIS AND CROHN'S DISEASE
June 3, 2016 EISAI INC. ENTERS INTO COLLABORATION AGREEMENT TO CO-PROMOTE EISAI'S ANTICANCER AGENT LENVIMA® IN COMBINATION WITH EVEROLIMUS AS TREATMENT FOR ADVANCED RENAL CELL CARCINOMA IN THE UNITED STATES
June 1, 2016 ANTICANCER AGENT HALAVEN® APPROVED IN THE PHILIPPINES FOR NEW INDICATION FOR TREATMENT OF SOFT TISSUE SARCOMA
SECOND COUNTRY IN ASIA AFTER JAPAN TO APPROVE HALAVEN FOR SOFT TISSUE SARCOMA
June 1, 2016 AbbVie and Eisai Subsidiary EA Pharma Commence Co-promotion of Fully Human Anti-TNF-α Monoclonal Antibody HUMIRA® in the Field of Gastrointestinal Disease
May 31, 2016 Notification Regarding the Completion of the Disposal of Treasury Stock Through Third-Party Allotment in Accordance with the Continuation of Performance-Related Stock Compensation System
May 25, 2016 EISAI TO LAUNCH IN-HOUSE DEVELOPED ANTIEPILEPTIC DRUG FYCOMPA® (PERAMPANEL HYDRATE) AS ADJUNCTIVE THERAPY FOR PARTIAL-ONSET AND GENERALIZED TONIC-CLONIC SEIZURES IN JAPAN
May 24, 2016 EISAI TO PRESENT NEW RESEARCH ON ONCOLOGY PRODUCTS AND PIPELINE AT 52ND ASCO ANNUAL MEETING
May 16, 2016 U.S. FDA APPROVES ADDITIONAL INDICATION FOR EISAI’S ANTICANCER AGENT LENVIMA® IN COMBINATION WITH EVEROLIMUS AS TREATMENT FOR ADVANCED RENAL CELL CARCINOMA
May 13, 2016 ANTICANCER AGENT HALAVEN® DEMONSTRATES STATISTICALLY SIGNIFICANT EXTENSION IN PROGRESSION FREE SURVIVAL COMPARED TO VINORELBINE IN PHASE III CLINICAL STUDY OF PATIENTS WITH BREAST CANCER IN CHINA
May 13, 2016 Notification Regarding the Disposal of Treasury Stock through Third-Party Allotment in Accordance with the Continuation of Performance-Related Stock Compensation System
May 13, 2016 Notification Regarding the Continuation and Partial Revision of the Performance-Related Stock Compensation System
May 6, 2016 EISAI RECEIVES APPROVAL FOR NEW INDICATION FOR ANTICANCER AGENT HALAVEN® FOR TREATMENT OF ADVANCED LIPOSARCOMA IN EUROPE
April 26, 2016 CONTINUATION OF “POLICY FOR PROTECTION OF THE COMPANY'S CORPORATE VALUE AND COMMON INTERESTS OF SHAREHOLDERS (SHAREHOLDER RIGHTS PLAN)”
April 20, 2016 EISAI TO SUPPORT RELIEF EFFORTS FOR 2016 KUMAMOTO EARTHQUAKES
April 20, 2016 EISAI ANNOUNCES NON-CLINICAL RESEARCH FINDINGS AT AACR 107TH ANNUAL MEETING REGARDING COMBINATION OF ANTICANCER AGENT LENVATINIB WITH EVEROLIMUS
ENHANCED MECHANISM OF ANGIOGENESIS INHIBITION AND ANTI-TUMOR ACTIVITY IN RENAL CELL CARCINOMA INVESTIGATED
April 14, 2016 ARICEPT® APPROVED IN THE PHILIPPINES FOR NEW INDICATION AS TREATMENT FOR DEMENTIA WITH LEWY BODIES
SECOND COUNTRY IN THE WORLD AFTER JAPAN TO APPROVE ARICEPT FOR DEMENTIA WITH LEWY BODIES
April 5, 2016 EISAI RECEIVES POSITIVE CHMP OPINION ON NEW INDICATION FOR ANTICANCER AGENT HALAVEN® FOR TREATMENT OF ADVANCED LIPOSARCOMA
March 31, 2016 EISAI TRANSFERS THE RIGHTS TO INVESTIGATIONAL ANTICANCER AGENT E7777 FOR EUROPEAN, U.S. AND CERTAIN EMERGING MARKETS TO DR. REDDY'S LABORATORIES
March 30, 2016 EISAI CO., LTD. AND AJINOMOTO CO., INC. ANNOUNCE ESTABLISHMENT OF GASTROINTESTINAL SPECIALTY PHARMA EA PHARMA CO., LTD. THROUGH THE INTEGRATION OF EISAI'S GASTROINTESTINAL DISEASE BUSINESS AND AJINOMOTO PHARMACEUTICALS CO., LTD.
March 30, 2016 Notification Regarding Revision of Consolidated Financial Results Forecasts (IFRS) for the Fiscal Year Ending March 31, 2016
March 30, 2016 EISAI'S U.S. SUBSIDIARY EISAI INC. ENTERS SHARE PURCHASE AGREEMENT CONCERNING AKARX INC. IN THE U.S.
RIGHTS TO IN-HOUSE DEVELOPED THROMBOCYTOPENIA TREATMENT AVATROMBOPAG TO BE TRANSFERRED
March 30, 2016 Notice Concerning Shelf Registration for Issuance of Stock Options
March 28, 2016 EISAI'S IN-HOUSE DEVELOPED ANTIEPILEPTIC DRUG FYCOMPA® (PERAMPANEL HYDRATE) APPROVED IN JAPAN AS ADJUNCTIVE THERAPY FOR PARTIAL-ONSET AND GENERALIZED TONIC-CLONIC SEIZURES
March 22, 2016 EISAI WITHDRAWS NEW DRUG APPLICATION FOR MECOBALAMIN ULTRA-HIGH DOSE PREPARATION AS TREATMENT FOR AMYOTROPHIC LATERAL SCLEROSIS
March 22, 2016 JOINT PROMOTION AGREEMENT ON ANTIEMETIC AGENT WITH HELSINN THERAPEUTICS INC. IN THE UNITED STATES REVISED
Eisai to Return All Rights to Promote and Distribute AKYNZEO® (netupitant/palonosetron) to Helsinn Therapeutics Inc.
March 17, 2016 NOTICE REGARDING DISCONTINUATION OF SALES AND VOLUNTARY RECALL OF EGG WHITE LYSOZYME PREPARATION NEUZYM®
March 1, 2016 Notification Regarding Change in Representative Corporate Officers
February 29, 2016 EISAI'S ANTICANCER AGENT HALAVEN® NEWLY APPROVED IN JAPAN FOR TREATMENT OF SOFT TISSUE SARCOMA
February 29, 2016 AbbVie and Eisai Clear All-Case Surveillance Condition for Approval of HUMIRA®, a Fully Human Anti-TNF-α Monoclonal Antibody, in the Treatment of Polyarticular Juvenile Idiopathic Arthritis
February 15, 2016 EISAI AND SYSMEX ENTER COMPREHENSIVE AGREEMENT TO CREATE NEXT-GENERATION DIAGNOSTIC REAGENTS IN THE FIELD OF DEMENTIA
February 12, 2016 PHASE III TRIAL RESULTS OF EISAI'S ANTICANCER AGENT HALAVEN® IN SOFT TISSUE SARCOMA PUBLISHED IN THE LANCET
February 2, 2016 Notification Regarding Revision of Consolidated Financial Results Forecasts (IFRS) for the Fiscal Year Ending March 31, 2016
February 1, 2016 EISAI ACQUIRES EXCLUSIVE LICENSE FROM HUYA BIOSCIENCE INTERNATIONAL TO DEVELOP AND MARKET HDAC INHIBITOR HBI-8000 IN JAPAN AND OTHER ASIAN COUNTRIES
January 29, 2016 U.S. FDA APPROVES EISAI’S ANTICANCER AGENT HALAVEN® FOR THE TREATMENT OF ADVANCED LIPOSARCOMA
January 18, 2016 U.S. FDA ACCEPTS FOR PRIORITY REVIEW sNDA FOR EISAI’S ANTICANCER AGENT LENVATINIB SEEKING APPROVAL FOR RENAL CELL CARCINOMA
January 12, 2016 EISAI SUBMITS NEW APPLICATION IN EUROPE FOR IN-HOUSE DEVELOPED ANTICANCER AGENT LENVATINIB SEEKING APPROVAL FOR INDICATION COVERING RENAL CELL CARCINOMA
APPLICATION BASED ON RESULTS OF PHASE II CLINICAL STUDY

Back to Top